Skip to main content

Advertisement

SpringerLink
Log in

O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Convection-enhanced delivery (CED) of paclitaxel is a new locoregional approach for patients with recurrent glioblastoma. The aim of this study was to evaluate O-(2-[18F]fluoroethyl)-l-tyrosine (FET) positron emission tomography (PET) in monitoring the effects of this type of direct drug delivery.

Methods

Eight patients with recurrent glioblastoma underwent CED of paclitaxel, which was infused over stereotactically placed catheters into the tumour. FET PET and MRI were performed before and 4 weeks after therapy and then at 3-month intervals to document follow-up. For quantitative evaluation, SUVmax(tumour)/SUVmean(background) ratios were calculated.

Results

At baseline all tumours showed gadolinium enhancement and high FET uptake (SUVmax/BG 3.2±0.8). Four weeks after CED, a statistically significant decrease in FET uptake was seen (SUVmax/BG −17%; p<0.01). During follow-up, no recurrence was observed within the CED area. Two out of eight patients with extended tumours died 4 and 5 months after treatment, most probably from local complications. Temporarily stable disease with stable FET uptake was observed in six of eight patients; this was followed by progression and increasing FET uptake ratios (+46%) distant from the CED area in five of the six patients 3–13 months after CED. One patient still presents stable FET uptake 10 months after CED. MRI showed unchanged/increasing contrast enhancement and oedema without ability to reliably assess disease progression.

Conclusion

FET PET is a valuable tool in monitoring the effects of CED of paclitaxel. In long-term follow-up, stable or decreasing FET uptake, even in contrast-enhancing lesions, is suggestive of reactive changes, whereas increasing ratios appear always to be indicative of recurrence. Therefore, FET PET is more reliable than MRI in differentiating stable disease from tumour regrowth.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Black PM. Brain tumors: part 1. N Engl J Med 1991;324:1471–6.

    CAS  PubMed  Google Scholar 

  2. Black PM. Brain tumor: part 2. N Engl J Med 1991;324:1555–64.

    CAS  PubMed  Google Scholar 

  3. Harbaugh KS, Black PM. Strategies in the surgical management of malignant gliomas. Semin Surg Oncol 1998;14:26–33.

    CAS  PubMed  Google Scholar 

  4. Devaux BC, O’Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767–75.

    CAS  PubMed  Google Scholar 

  5. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Investig 1996;14:551–9.

    CAS  Google Scholar 

  6. Read TA, Thorsen F, Bjerkvig R. Localised delivery of therapeutic agents to CNS malignancies: old and new approaches. Curr Pharm Biotechnol 2002;3:257–73.

    CAS  PubMed  Google Scholar 

  7. Patchell RA, Regine WF, Ashton P, Tibbs PA, Wilson D, Shappley D, et al. A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002;60:37–42.

    PubMed  Google Scholar 

  8. Westphal M, Lamszus K, Hilt D. Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir, Suppl 2003;88:61–7.

    Google Scholar 

  9. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82:1021–9.

    CAS  PubMed  Google Scholar 

  10. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076–80.

    CAS  PubMed  Google Scholar 

  11. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971–3.

    CAS  PubMed  Google Scholar 

  12. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377–84.

    CAS  PubMed  Google Scholar 

  13. Earnest F, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823–7.

    PubMed  Google Scholar 

  14. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542–9.

    CAS  PubMed  Google Scholar 

  15. Voges J, Herholz K, Holzer T, Wurker M, Bauer B, Pietrzyk U, et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 1997;69:129–35.

    CAS  PubMed  Google Scholar 

  16. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-11C-methionine. Am J Neuroradiol 1996;17:345–53.

    CAS  PubMed  Google Scholar 

  17. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.

    CAS  PubMed  Google Scholar 

  18. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459–62.

    CAS  PubMed  Google Scholar 

  19. Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, et al. [11C]l-methionine uptake in gliomas. Neurosurgery 1989;25:720–8.

    CAS  PubMed  Google Scholar 

  20. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464–70.

    PubMed  Google Scholar 

  21. Wurker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583–6.

    CAS  PubMed  Google Scholar 

  22. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45–53.

    CAS  PubMed  Google Scholar 

  23. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316–22.

    CAS  PubMed  Google Scholar 

  24. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269–71.

    CAS  PubMed  Google Scholar 

  25. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T, et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056–64.

    PubMed  Google Scholar 

  26. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989;30:121–8.

    CAS  PubMed  Google Scholar 

  27. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;54:2207–12.

    CAS  PubMed  Google Scholar 

  28. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, et al. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (taxol) in vitro. Br J Cancer 1997;75:1744–52.

    CAS  PubMed  Google Scholar 

  29. Cahan MA, Walter KA, Colvin OM, Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994;33:441–4.

    CAS  PubMed  Google Scholar 

  30. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004;100:472–9.

    CAS  PubMed  Google Scholar 

  31. Bruce JN, Falavigna A, Johnson JP, Hall JS, Birch BD, Yoon JT, et al. Intracerebral clysis in a rat glioma model. Neurosurgery 2000;46:683–91.

    CAS  PubMed  Google Scholar 

  32. Kaiser MG, Parsa AT, Fine RL, Hall JS, Chakrabarti I, Bruce JN. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000;47:1391–8.

    CAS  PubMed  Google Scholar 

  33. Voges J, Reszka R, Gossmann A, Dittmar C, Richter R, Garlip G, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003;54:479–87.

    CAS  PubMed  Google Scholar 

  34. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Holtmannspoetter M, Tonn JC, et al. [18F]FET PET for monitoring the effects of intralesional radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2003;30:S189–90.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Klinikum Grosshadern, University of Munich, Marchioninistrasse 15, 81377, Munich, Germany

    G. Pöpperl, F. J. Gildehaus & K. Tatsch

  2. Department of Neurosurgery, Klinikum Grosshadern, University of Munich, Munich, Germany

    R. Goldbrunner, F. W. Kreth, P. Tanner & J. C. Tonn

  3. Department of Neuroradiology, Klinikum Grosshadern, University of Munich, Munich, Germany

    M. Holtmannspötter

Authors
  1. G. Pöpperl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Goldbrunner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. J. Gildehaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. W. Kreth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Tanner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Holtmannspötter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. C. Tonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Pöpperl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pöpperl, G., Goldbrunner, R., Gildehaus, F.J. et al. O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32, 1018–1025 (2005). https://doi.org/10.1007/s00259-005-1819-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1819-7

Keywords

Search

Navigation